Samuel W. Du

Samuel W. Du

Auto-generated profile, based on publicly available information

Samuel W. Du

Gavin Herbert Eye Institute-Center for Translational Vision Research, Department of Ophthalmology

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
ZEZachary J. Engfer
Zachary J. Engfer
GPGrazyna Palczewska
Grazyna Palczewska
SDSamuel W. Du
Samuel W. Du
JZJianye Zhang
Jianye Zhang
ZDZhiqian Dong
Zhiqian Dong
KPKrzysztof Palczewski
Krzysztof Palczewski
11- cis -Retinal is essential for light perception in mammalian photoreceptors (PRs), and aberrations in retinoid transformations cause severe retinal diseases. Understanding these processes is crucial for combating blinding diseases. The visual cycle, operating within PRs and the retinal pigment epithelium (RPE), regenerates 11- cis -retinal to sustain light sensitivity. Retinoids are also present in Müller glia (MG), hypothesized to supply 11- cis -retinol to cone PRs and retinal ganglion cells (RGCs). To trace retinoid movement through retinal cell types, we used cell-specific knockin of lecithin:retinol acyltransferase (LRAT), which converts retinols into stable retinyl esters (REs). Ectopic LRAT expression in murine PRs, MG, and RGCs resulted in RE synthesis, with REs differing in abundance and isomeric composition across cell types under genetic and light-based perturbations. PR inner segments showed high 11- cis -RE content, suggesting a constant 11- cis -retinoid supply for pigment regeneration. In MG expressing LRAT, all- trans -REs were detected, contrasting with 11- cis -REs in PRs. The MG-specific LRAT phenotype mirrored the RE-rich human neural retina, suggesting human MG may utilize LRAT to maintain retinoid reservoirs. Our findings reveal tightly controlled retinoid flux throughout the mammalian retina that supports sustained vision, expanding understanding of the visual cycle to combat retinal diseases.

11 December 2025 in JCI Insight
Verified
Journal Article
Open access
PDF file
BKBalasankara Reddy Kaipa
Balasankara Reddy Kaipa
LLLinya Li
Linya Li
PKPrakadeeswari Gopala Krishnan
Prakadeeswari Gopala Krishnan
SDSamuel Du
Samuel Du
JFJiin Felgner
Jiin Felgner
GZGulab S. Zode
Gulab S. Zode
Mutations in MYOC , the most common genetic cause of glaucoma, cause misfolded myocilin to accumulate in the endoplasmic reticulum (ER), leading to trabecular meshwork (TM) dysfunction, elevated intraocular pressure, and progressive vision loss. While gene editing offers curative potential, current delivery methods rely on viral vectors, which are limited by inflammation, off-target effects, and poor translatability. Here, we report a nonviral lipid nanoparticle (LNP) platform that enables selective in vivo delivery of mRNA encoding an adenine base editor and single guide RNA (LNP-ABE) to TM cells. A direct comparison of LNP-mCherry with lentiviral GFP revealed that LNPs outperform viral vectors, achieving markedly higher efficiency and greater selectivity for the TM without inducing ocular inflammation. In a Cre-inducible Tg.CreMYOC Y437H glaucoma mouse model, LNP-Cre mRNA selectively induced mutant MYOC expression in the TM, faithfully recapitulating key disease features. A single administration of LNP-ABE achieved efficient on-target editing of mutant MYOC , reducing mutant myocilin protein by approximately 46%, decreasing aggregates, alleviating ER stress, and fully rescuing the glaucomatous phenotype in Tg.CreMYOC Y437H mice. Importantly, no off-target editing or ocular toxicity was detected. These findings establish LNP-based mRNA delivery as a safe, efficient, and clinically translatable approach for TM-targeted genome editing with broad therapeutic potential in glaucoma.